Alpha Teknova Posted Record Revenue, Narrowed Its Loss, and Raised Guidance in the Same Quarter

Alpha Teknova, a small manufacturer of reagents and lab-essential supplies used in life-sciences research, reported second-quarter 2026 revenue of $12.19 million on August 5, 2026 — a company record, up 18% year over year and well above the $10.97 million analysts had estimated. The adjusted loss per share narrowed to $0.06 from an expected $0.08 loss. Gross margin expanded 1.4 percentage points to 40.1%, and free cash outflow narrowed to $0.6 million from $2.3 million in the same quarter a year earlier.

Alpha Teknova also raised its full-year 2026 revenue guidance to $45 million-$47 million from a prior $42 million-$44 million range, citing increased confidence in demand across both its Lab Essentials and Clinical Solutions product lines. For a small company still working toward sustained profitability, a quarter that combines a revenue record, a narrower loss, expanding margin, and a guidance raise — with no offsetting weak spot in the release — is a genuinely clean set of results, distinct from the more common pattern this earnings season of strong headline numbers paired with a concerning detail elsewhere in the report.

Alpha Teknova had already been one of the market's stronger performers heading into this report, and today's reaction extends that run on results that, unlike many of this week's earnings reactions, do not require unpacking a contradiction between the headline and the guidance — both point the same direction.